EGFR and brain neoplasm: Besides direct VEGF or VEGFR2 inhibition for glioblastoma, clinical studies are being conducted or planned with agents targeting further downstream or alternative pathways frequently altered in brain tumors, including the mTOR/Akt and EGFR pathways [39].